Format

Send to

Choose Destination
Bone Marrow Transplant. 2018 Apr;53(4):499-502. doi: 10.1038/s41409-017-0046-8. Epub 2018 Jan 12.

Donor HSCs with a preexisting ASXL1-mutation led to the development of FLT3-ITD positive AML in the donor and FLT3-ITD negative AML in the recipient after unrelated transplant.

Author information

1
Department of Hematology, Henan Provincial People's Hospital and Zhengzhou University People's Hospital, #7 Weiwu Road, Zhengzhou, Henan, 450003, China.
2
Clinical Laboratory Division, Hebei Yanda Lu Daopei Hospital, Hebei, 065201, China.
3
Henan Tumor Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan, 450008, China.
4
Henan Provincial Center for China Marrow Donor Program (CMDP), #32 Zheng-qi Street, Zhengzhou, Henan, 450003, China.
5
Department of Pathology and Lab Medicine, University of Texas, Southwestern Medical Center, BioCenter, 2330 Inwood Rd. EB3.234 A, Dallas, TX, 75390, USA.
6
Department of Dermatology, School of Medicine, University of California-Davis, Sacramento, CA, 95817, USA.
7
Department of Hematology, Henan Provincial People's Hospital and Zhengzhou University People's Hospital, #7 Weiwu Road, Zhengzhou, Henan, 450003, China. sunkai@cellscience.org.
PMID:
29330388
DOI:
10.1038/s41409-017-0046-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center